TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01500109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral acetaminophen
Description: Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofirmev®
Description: Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opioid only
Description: Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
Study: NCT03507387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenylephrine
Description: 5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
Study: NCT01991782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients in the telemedicine cohort will have two follow-up visits (at 6 weeks and 6 months) through video calls.
Study: NCT00343421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEDIACEL® and Prevenar®
Description: 0.5 mL each, IM (opposite thigh)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix®-IPV+Hib and Prevenar®
Description: 0.5 mL each, IM (opposite thigh)
Study: NCT02872740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of Left Gastric Artery
Description: Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of Gastroepiploic Artery
Description: Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
Study: NCT02645357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer reminders on clinical practice
Description: on-screen, point-of-care computer reminders on clinical practice.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: control group
Study: NCT01609907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 1)
Description: Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 2)
Description: Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 3)
Description: Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study: NCT03507387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: All patients will receive spinal anesthesia with bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: All patients will receive spinal anesthesia with bupivacaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: All patients will receive spinal anesthesia with bupivacaine.
Study: NCT01146717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients with mild cognitive impairment will undergo moderate intensity endurance exercise training for one year.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Balance training
Description: A group of patients with mild cognitive impairment will perform flexibility and balance training for one year as a control group.
Study: NCT01609907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 4)
Description: Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 5)
Description: Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Valsartan (Sequence 6)
Description: Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study: NCT00423917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Study: NCT03807921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral anticoagulation
Study: NCT02131558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG Dye
Description: ICG Dye injections
Study: NCT01677533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data
Description: The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data
Description: The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data
Description: The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Panel Management Support
Description: PMAs will meet regularly with the members of the microsystem team for one hour/week. The team will be asked to review progress on the health status of their patient panel and to plan strategies for improving their outcomes that the PMA will then implement. A PMA toolkit of panel management strategies will be established that will include guidelines for using VA databases to identify care gaps and reaching out to panel patients via phone and mail to intervene (e.g. reconnect patients to care with appointments, assess and enhance medication adherence, connect patients with VA services, motivational interviewing, and communication with the team about patient issues.
Study: NCT03807921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Antiplatelet treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Antiplatelet treatment
Study: NCT01677533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Panel Management Support
Description: PMAs will meet regularly with the members of the microsystem team for one hour/week. The team will be asked to review progress on the health status of their patient panel and to plan strategies for improving their outcomes that the PMA will then implement. A PMA toolkit of panel management strategies will be established that will include guidelines for using VA databases to identify care gaps and reaching out to panel patients via phone and mail to intervene (e.g. reconnect patients to care with appointments, assess and enhance medication adherence, connect patients with VA services, motivational interviewing, and communication with the team about patient issues.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The educational intervention will be administered throughout the duration of the study. Our initial educational focus will be on content (concepts of population health and panel management) and process (practice change methodology). Subsequent education will be process oriented, reviewing the changing system of care and discussing its functioning. Education will cover panel management strategies, microsystem theory and skills, and specific strategies regarding the management of hypertension and smoking cessation. It will include monthly seminars, reading materials, web-based modules, and skill building workshops, and PMA-conducted monthly academic detailing using panel data and feedback. After the first three months, academic detailing will only be implemented on an as-needed basis.
Study: NCT03842423

Intervention type: PROCEDURE
Intervention: Brachial Plexus Anaesthesia
Description: Regional anaesthesia for treatment of upper extremity injuries.
Study: NCT03085797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations \[50 g/actuation\] in each nostril once daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate
Description: All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations \[50 g/actuation\] in each nostril once daily).
Study: NCT00697138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-Amphetamine; Atomoxetine
Description: Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
Study: NCT04161248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP~Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Injection
Description: 375 mg/m2 - Day 1, cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Injection
Description: 375 mg/m2 - Day 1, cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab SC
Description: 1400 mg fixed dose - Day 1, cycle 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab SC
Description: 1400 mg fixed dose - Day 1, cycle 2 and 3
Study: NCT01409733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE using Drug Eluting Beads loaded with Doxorubicin
Description: 100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
Study: NCT04161248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 - Day 1 to day 8
Study: NCT04065555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-981
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAK-981 + Cetuximab
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAK-981 + Avelumab
Description: Intratumoral microdose injection by the CIVO device.
Study: NCT02185950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paraffin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paraffin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endermotherapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endermotherapy
Study: NCT02678481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-guided in-bore prostate biopsy
Description: 2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
Study: NCT04161248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 - Day 1 to day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg daily - Day 1 to day 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg daily - Day 1 to day 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 - Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 - Day 1
Study: NCT02678481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUS-guided prostate biopsy
Description: 24-28 systematic biopsy core (saturation scheme)
Study: NCT02960828

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subthreshold Laser Photocoagulation
Description: Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal Anti-VEGF injection
Description: To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
Study: NCT04161248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Cycle 1: Glofitamab 2.5 mg (day 8) and 10 mg (day 15) + R-GDP Cycle 2: Glofitamab 30 mg (day 8) + R-GDP Cycle 3: Glofitamab 30 mg (day 8) + R-GDP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Cycle 1: Tafasitamab (12 mg/kg IV day -1, 8, 15) Cycles 2 and 3: Tafasitamab (12 mg/kg IV day 1, 8, 15)
Study: NCT02960828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subthreshold Laser
Study: NCT00859911

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients
Description: A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
Study: NCT03914807

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole (3.25%) cow's milk recommendation
Description: Children randomized to the whole milk recommendation will receive a recommendation a primary care recommendation to consume 500 mL of whole fat (3.25%) milk instead of transitioning to reduced fat (1%) milk at 2 years of age. The primary care physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children in the whole milk recommendation group will be provided with the same age-appropriate nutritional recommendations as children in the reduced fat recommendation group as part of routine healthcare according to the Rourke Baby Record.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduced (1%) fat milk
Description: Children randomized to the reduced fat group will receive a primary care recommendation to transition from whole milk to 500 mL reduced fat (1%) milk daily once the child is two years of age (consistent with current guidelines). The physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children who receive the reduced fat recommendation will be provided with the same age-appropriate nutritional recommendations as children who receive the whole fat recommendation as part of routine healthcare according to the Rourke Baby Record.
Study: NCT00750958

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: NetGuard Automated Clinician Alert System
Description: Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
Study: NCT00859911

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple micronutrients
Description: A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
Study: NCT01077843

Intervention type: DRUG
Intervention: Etoricoxib
Description: Cox-2 inhibitor

Intervention type: DRUG
Intervention: Other Cox-2 inhibitors
Description: Cox-2 inhibitor

Intervention type: DRUG
Intervention: Other Non-selective NSAIDs
Description: Non-selective NSAID

Intervention type: OTHER
Intervention: No anti-inflammatory treatment
Description: No anti-inflammatory prescription
Study: NCT02933034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manganese-enhanced MRI contrast reagent
Description: MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI contrast reagent
Description: MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).
Study: NCT04052685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective removal to soft dentin (SRSD)
Description: In order to prevent pulp exposure in deep caries lesions radiographically extending at least 3/4 of dentin, periphery of the cavity prepared to hard dentin while reasonable amount of soft carious tissue over the pulp is left. This caries removal strategy is termed selective removal to soft dentine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective removal to firm dentine (SRFD)
Description: Carious tissue is totally removed until hard dentin dry in appearance and hard on probing. This carious removal strategy is strongly recommended for shallow or moderately deep carious lesions.
Study: NCT04252846

Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel oral tablets or oral suspension.
Study: NCT04343625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified yoga class
Description: Modified yoga was used to see if it would improve pain, fatigue, depression and anxiety, as well as improve sleep quality.
Study: NCT03496220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angulus
Description: Feedback on patient recumbency

Intervention type: DEVICE
Group type: OTHER
Intervention: Angulus
Description: Feedback on patient recumbency